Regen BioPharma Inc. (OTCQB: RGBP) and (OTCQB: RGBPP) continues to develop small molecule drugs that activate NR2F6 and has identified a key structural element whose presence in small molecules seems to be required for activation of NR2F6. These studies were conducted at ChemDiv Inc., the Company’s contract research organization.

Leave a Reply

Your email address will not be published.